MINNEAPOLIS, May 31, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued guidance on percutaneous tibial nerve stimulation (PTNS) for the treatment of faecal incontinence. In October 2010, NICE issued similar guidance on PTNS treatment for overactive bladder.
"This NICE guidance should encourage physicians in the UK and Europe to use our Urgent® PC Neuromodulation System for PTNS treatments for this often difficult-to-treat affliction. This guidance affirms the evidence that PTNS is efficacious in reducing the symptoms of faecal incontinence without major safety concerns," said David Kaysen, President and CEO of Uroplasty.
In the UK, NICE makes recommendations to the National Health Service on new and existing medicines, treatments and procedures with the goal of improving health and treating and preventing poor health. A copy of the NICE guidance may be found at www.nice.org.uk.
About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC Neuromodulation System, which we believe is the only FDA-cleared minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.
We also offer Macroplastique Implants®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking Information This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. For Further Information:Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, 952.426.6140 EVC Group
Doug Sherk/Jenifer Kirtland (Investors)
Chris Gale (Media)
|SOURCE Uroplasty, Inc.|
Copyright©2010 PR Newswire.
All rights reserved